News
Byondis begins patient dosing in phase 1 trial of novel SIRPa-directed mAb BYON4228 in patients with advanced or metastatic solid tumours: Nijmegen, The Netherlands Wednesday, Jun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback